Search results
Results from the WOW.Com Content Network
Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [ 7 ] Pomalidomide was approved for medical use in the United States in February 2013, [ 10 ] and in the European Union in August 2013. [ 8 ]
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.
Elotuzumab is recommended through intravenous administration at 10 mg/kg each week for the first 2 cycles (each cycle is 28 days). [3] At the start of cycle 3, administer 20 mg/kg every 4 weeks, while administering the recommended dose of pomalidomide and low dose dexamethasone. [3]
[10] [11] While it was initially thought to be safe in pregnancy, concerns regarding birth defects arose, resulting in its removal from the market in Europe in 1961. [9] [10] The total number of infants severely harmed by thalidomide use during pregnancy is estimated at over 10,000, possibly 20,000, of whom about 40% died around the time of birth.
Nearly one in five new cervical cancers diagnosed from 2009 to 2018 were in women 65 and older, according to a new UC Davis study.But what has experts concerned is that, according to the study ...
Feet of a baby born to a mother who had taken thalidomide while pregnant. In the late 1950s and early 1960s, the use of thalidomide in 46 countries was prescribed to women who were pregnant or who subsequently became pregnant, and consequently resulted in the "biggest anthropogenic medical disaster ever," with more than 10,000 children born with a range of severe deformities, such as ...
The therapeutic index (TI; also referred to as therapeutic ratio) is a quantitative measurement of the relative safety of a drug with regard to risk of overdose.It is a comparison of the amount of a therapeutic agent that causes toxicity to the amount that causes the therapeutic effect. [1]
Myelosuppression is the major dose-limiting toxicity, which is not the case with thalidomide. [ 26 ] Lenalidomide may be associated with adverse effects as second primary malignancy , severe cutaneous reactions, hypersensitivity reactions , tumor lysis syndrome , tumor flare reaction, hypothyroidism , and hyperthyroidism .